Boothbay Fund Management, LLC Cabaletta Bio, Inc. Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $813,559 - $1.23 Million	-48,455 Reduced 82.47%	10,300 $175,000
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $717,398 - $1.37 Million	58,755 New	58,755 $1.33 Million
Q1 2023 May 15, 2023	SELL	$7.08 - $12.62 $10,662 - $19,005	-1,506 Reduced 10.73%	12,528 $103,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $1,912 - $27,788	-2,988 Reduced 17.55%	14,034 $129,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $2.05 $46,478 - $151,240	-73,776 Reduced 81.25%	17,022 $11,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $2.11 $12,426 - $26,484	-12,552 Reduced 12.15%	90,798 $96,000
Q4 2021 Feb 14, 2022	SELL	$3.36 - $14.64 $55,722 - $242,789	-16,584 Reduced 13.83%	103,350 $392,000
Q3 2021 Nov 15, 2021	BUY	$7.0 - $12.5 $43,995 - $78,562	6,285 Added 5.53%	119,934 $1.46 Million
Q2 2021 Aug 16, 2021	BUY	$7.2 - $11.73 $495,316 - $806,953	68,794 Added 153.37%	113,649 $977,000
Q1 2021 May 17, 2021	BUY	$10.39 - $14.53 $466,043 - $651,743	44,855 New	44,855 $498,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.